sb 203580 has been researched along with eriodictyol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (eriodictyol) | Trials (eriodictyol) | Recent Studies (post-2010) (eriodictyol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 179 | 0 | 114 |
| Protein | Taxonomy | sb 203580 (IC50) | eriodictyol (IC50) |
|---|---|---|---|
| Cytochrome P450 1B1 | Homo sapiens (human) | 1.284 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhutani, KK; Garg, D; Kadam, RU; Paul, AT; Roy, N | 1 |
1 other study(ies) available for sb 203580 and eriodictyol
| Article | Year |
|---|---|
Evaluation of proinflammatory cytokine pathway inhibitors for p38 MAPK inhibitory potential.
Topics: Anti-Inflammatory Agents; Biflavonoids; Cytokines; Flavanones; Flavones; Flavonoids; Glucosides; Hydrogen Bonding; Imidazoles; Luteolin; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Pyridines; Structure-Activity Relationship | 2007 |